Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
Disclosed are methods useful for the topical therapeutic treatment of skin malignancies including skin cancers and cutaneous metastases using compositions containing nanoparticles of paclitaxel or other taxanes.
1. A method of treating a skin malignancy in a subject in need of treatment, the method comprising topically administering to an affected area of the subject a hydrophobic composition comprising a plurality of nanoparticles of non-solubilized taxane, greater than 50% w/w of a hydrophobic carrier, and 5% w/w to 24% w/w of one or more volatile silicone fluids,
wherein the nanoparticles of non-solubilized taxane are uncoated (neat) individual particles of non-solubilized taxane,
wherein the non-solubilized taxane is not bound to or conjugated to any substance, and
wherein the taxane from the plurality of nanoparticles penetrates into the dermal or epidermal portions of the affected area of the subject.
2. The method of claim 1 , wherein the nanoparticles of non-solubilized taxane are in crystalline form.
3. The method of claim 1 , wherein the nanoparticles of non-solubilized taxane are in amorphous form.
4. The method of claim 1 , wherein the nanoparticles of non-solubilized taxane have a mean particle size (number) from 0.1 microns to 1.5 microns.
5. The method of claim 1 , wherein the taxane is paclitaxel.
6. The method of claim 5 , wherein the nanoparticles of non-solubilized taxane have a specific surface area (SSA) of 18 m 2 /g to 40 m 2 /g.
7. The method of claim 6 , wherein the nanoparticles of non-solubilized taxane contain not less than 90% by weight of paclitaxel.
8. The method of claim 1 , wherein the composition comprises 0.1% w/w to 5% w/w of the plurality of the nanoparticles of non-solubilized taxane.
9. The method of claim 1 , wherein the nanoparticles of non-solubilized taxane are suspended within the composition.
10. The method of claim 1 , wherein the composition is anhydrous.
11. The method of claim 1 , wherein the hydrophobic carrier is non-volatile and non-polar.
12. The method of claim 1 , wherein the hydrophobic carrier comprises a hydrocarbon.
13. The method of claim 12 , wherein the hydrocarbon is petrolatum, mineral oil, or paraffin wax, or mixtures thereof.
14. The method of claim 1 , wherein the one or more volatile silicone fluids is cyclomethicone.
15. The method of claim 1 , wherein the composition does not contain a C 1 -C 4 aliphatic alcohol, a surfactant, a protein, and/or a hyaluronic acid-taxane conjugate.
16. The method of claim 1 , wherein the skin malignancy is a skin cancer.
17. The method of claim 1 , wherein the skin cancer is melanoma, basal cell carcinoma, squamous cell carcinoma, or Kaposi's sarcoma.
18. The method of claim 1 , wherein the skin malignancy is a cutaneous metastasis.
19. The method of claim 18 , wherein the cutaneous metastasis is from lung cancer, breast cancer, colon cancer, oral cancer, ovarian cancer, kidney cancer, esophageal cancer, stomach cancer, liver cancer, or Kaposi's sarcoma.
20. A method of treating a skin malignancy in a subject in need of treatment, the method comprising topically administering to an affected area of the subject an anhydrous hydrophobic composition comprising a suspension of 0.1% w/w to 5% w/w of a plurality of nanoparticles of non-solubilized taxane, greater than 50% w/w of petrolatum, and 5% w/w to 24% w/w of cyclomethicone,
wherein the nanoparticles of non-solubilized taxane are uncoated (neat) individual particles of non-solubilized taxane,
wherein the non-solubilized taxane is not bound to or conjugated to any substance,
wherein the nanoparticles of non-solubilized taxane have a mean particle size (number) from 0.1 microns to 1.5 microns, and
wherein the skin malignancy is a cutaneous metastasis, and
wherein the taxane from the plurality of nanoparticles penetrates into the dermal or epidermal portions of the affected area of the subject.
21. The method of claim 20 , wherein the composition further comprises mineral oil or paraffin wax, or mixtures thereof.
22. The method of claim 21 , wherein the taxane is paclitaxel, and wherein the nanoparticles of non-solubilized taxane contain not less than 90% by weight of paclitaxel.
23. The method of claim 20 , wherein the nanoparticles of non-solubilized taxane have a specific surface area (SSA) of 18 m 2 /g to 40 m 2 /g.